TY - JOUR
T1 - Hyperspectral imaging reveals spectral differences and can distinguish malignant melanoma from pigmented basal cell carcinomas
T2 - A pilot study
AU - Räsänen, Janne
AU - Salmivuori, Mari
AU - Pölönen, Ilkka
AU - Grönroos, Mari
AU - Neittaanmäki, Noora
N1 - Funding Information:
This study was funded by the Cancer Foundation of Finland, by Tampere University Hospital and by the State Research Funding.
Funding Information:
The patients in this paper provided written informed consent for publication of their case details. The authors would like to thank Ulla Oesch-L??veri, nurse at the P?ij?t-H?me Central Hospital, for her dedication to this study, and Heikki Saari from VTT Finnish Technical Centre of Finland and statistician Martin Gillsted for their help in the study. This study was funded by the Cancer Foundation of Finland, by Tampere University Hospital and by the State Research Funding. IP, MG and NN have a patent (US10478071B2) licensed. MG has received a consultation fee from Revenio Group. The other authors have no conflicts of interest to declare.
Publisher Copyright:
© 2021, Medical Journals/Acta D-V. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Pigmented basal cell carcinomas can be difficult to distinguish from melanocytic tumours. Hyperspectral imaging is a non-invasive imaging technique that measures the reflectance spectra of skin in vivo. The aim of this prospective pilot study was to use a convolutional neural network classifier in hyperspectral images for differential diagnosis between pigmented basal cell carcinomas and melanoma. A total of 26 pigmented lesions (10 pigmented basal cell carcinomas, 12 melanomas in situ, 4 invasive melanomas) were imaged with hyperspectral imaging and excised for histopathological diagnosis. For 2-class classifier (melanocytic tumours vs pigmented basal cell carcinomas) using the majority of the pixels to predict the class of the whole lesion, the results showed a sensitivity of 100% (95% confidence interval 81-100%), specificity of 90% (95% confidence interval 60-98%) and positive predictive value of 94% (95% confidence interval 73-99%). These results indicate that a convolutional neural network classifier can differentiate melanocytic tumours from pigmented basal cell carcinomas in hyperspectral images. Further studies are warranted in order to confirm these preliminary results, using larger samples and multiple tumour types, including all types of melanocytic lesions.
AB - Pigmented basal cell carcinomas can be difficult to distinguish from melanocytic tumours. Hyperspectral imaging is a non-invasive imaging technique that measures the reflectance spectra of skin in vivo. The aim of this prospective pilot study was to use a convolutional neural network classifier in hyperspectral images for differential diagnosis between pigmented basal cell carcinomas and melanoma. A total of 26 pigmented lesions (10 pigmented basal cell carcinomas, 12 melanomas in situ, 4 invasive melanomas) were imaged with hyperspectral imaging and excised for histopathological diagnosis. For 2-class classifier (melanocytic tumours vs pigmented basal cell carcinomas) using the majority of the pixels to predict the class of the whole lesion, the results showed a sensitivity of 100% (95% confidence interval 81-100%), specificity of 90% (95% confidence interval 60-98%) and positive predictive value of 94% (95% confidence interval 73-99%). These results indicate that a convolutional neural network classifier can differentiate melanocytic tumours from pigmented basal cell carcinomas in hyperspectral images. Further studies are warranted in order to confirm these preliminary results, using larger samples and multiple tumour types, including all types of melanocytic lesions.
KW - Basal cell carcinoma
KW - Deep learning
KW - Malignant melanoma
KW - Neural network
U2 - 10.2340/00015555-3755
DO - 10.2340/00015555-3755
M3 - Article
C2 - 33521835
AN - SCOPUS:85102213363
SN - 0001-5555
VL - 101
JO - Acta dermato-venereologica
JF - Acta dermato-venereologica
IS - 2
M1 - adv00405
ER -